Table 2. Prevalence of abnormal celiac disease serum tests amongst among evaluable samples for participants in the IBS and control groups.

Test	Suspected IBS (n=492), n(%)	Healthy controls (n=458), n(%)	P value	aOR (95% CI)
Any abnormal celiac disease test	36 (7.32)	22 (4.8)	0.25	1.49 (0.76, 2.90)
AGA IgG	24 (4.88)	14 (3.06)	0.70	1.19 (0.50, 2.79)
AGA IgA	8 (1.63)	8 (1.75)	0.54	1.41 (0.47, 4.22)
EMA	3 (0.61)	2 (0.44)	0.66	1.65 (0.17, 15.42)
TTG IgA	6 (1.22)	2 (0.44)	0.15	3.87 (0.61, 24.74)
Total IgA (low)	3 (0.61)	3 (0.66)	0.93	0.93 (0.19, 4.62)
DQ2	164 (33.33)	180 (39.30)	0.004	0.61 (0.44, 0.86)
DQ8	81 (16.46)	83 (18.12)	0.54	1.14 (0.76, 1.70)

CD= celiac disease, AGA= antigliadin antibody, EMA=anti-endomysial antibody, TTG= anti-tissue transglutaminase antibody, IgG=immunoglobulin G, IgA=immunoglobulin A, aOR = adjusted odds ratio (for age and sex), CI = confidence interval